Program
torvutatug samrotecan
Also written as “Torvutatug samrotecan” and “AZD5335”.
Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms, led by AstraZeneca.
Furthest: phase 3, since Oct 16, 20255 company-led studies, 5 open or runningNext primary completion: Oct 15, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 55 open or running | phase 3since Oct 16, 2025 | Feb 21, 2023 | Oct 15, 2027phase 1 · NCT07402915 |
- Named in AstraZeneca’s own pipeline as
torvutatug samrotecan
, phase 3, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 21, 2023First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT05797168 · 622 planned · United States, Australia, Canada and more
- Oct 16, 2025Phase 3 study in Carcinoma, Ovarian EpithelialNCT07218809 · 1,100 planned · United States, Australia, Belgium and more
- Jan 23, 2026Phase 1 study in Fallopian Tube NeoplasmsNCT07402915 · 32 planned · Georgia, Ireland, Portugal and more
- Sep 7, 20262 phase 3 studiesNCT07816666, NCT07851025
Ahead
- Oct 15, 2027Primary completion: phase 1 study in Fallopian Tube NeoplasmsNCT07402915
- Aug 4, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT05797168
- Sep 29, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07816666
- Nov 17, 2028Primary completion: phase 3 study in Carcinoma, Ovarian EpithelialNCT07218809
TargetBeta
“An antibody-drug conjugate (ADC) composed of torvutatug, a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated to samrotecan, a linker conjugated to exatecan, with potential antineoplastic activity. Upon administration of torvutatug samrotecan, the antibody mo…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of torvutatug, a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mirvetuximab soravtansinerule | AbbVie | phase 3 | 15 |
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07851025Carcinoma, Ovarian Epithelial · United States, Argentina, Australia and more | 3 | Recruiting | Jun 28, 2030 | 950 |
| NCT07816666Ovarian Neoplasms · United States, Australia, Brazil and more | 3 | Recruiting | Sep 29, 2028 | 600 |
| NCT07402915Fallopian Tube Neoplasms · Georgia, Ireland, Portugal and more | 1 | Recruiting | Oct 15, 2027 | 32 |
| NCT07218809Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more | 3 | Recruiting | Nov 17, 2028 | 1,100 |
| NCT05797168Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Aug 4, 2028 | 622 |
How it is read
Names in the registry
- “Torvutatug samrotecan”, 3 entries
- “AZD5335”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 3 studies
- Ovarian Neoplasms, 1 study
- Fallopian Tube Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.